( IRVINE Calif. May 30 2007 /PRNewswi...)IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting,Health

IRVINE, Calif., May 30, 2007 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. today announced that data from a Phase II Uvidem melanoma vaccine clinical trial and data from the Phase II EP-2101 non-small cell lung cancer (NSCLC) vaccine clinical trial will be presented at the 2007 American Society of Clinical Oncology (ASCO) 43rd annual meeting in Chicago on June 1-5 2007.

    UVIDEM presentation details:


    --  "Clinical and immunological responses in patients with malignant

        melanoma treated with a dendritic cell-based vaccine. Preliminary

        report from a multi-institutional phase II clinical trial." Abstract

        # 3004, Session: Developmental Therapeutics: Immunotherapy. Oral

        presentation by Merrick I. Ross, M.D., Professor of Surgery, Chief,

        Melanoma Section, Department of Surgical Oncology at M. D. Anderson

        Cancer Center.

    --  June 5, 2007 at 7.45 AM

    --  Location: E354a



    EP-2101 presentation details:


    --  "Phase II trial of a 10-epitope CTL vaccine, EP-2101, in metastatic

        NSCLC patients." Abstract # 3068, Session: Developmental Therapeutics:

        Immunotherapy. Poster presentation.

    --  June 3, 2007, 8.00 AM - 12 PM

    --  Location: S Hall A2

About the UVIDEM(R) Clinical Trial

The U.S. clinical trial is designed to assess the safety and clinical activity of UVIDEM in patients with stage III or IV melanoma with measurable lesions. Participating centers include the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, the MD Anderson Cancer Center, the University of Pittsburgh, the Arizona Cancer Center and Lutheran General Cancer Care Center

About the EP-2101 Clinical Trial

The U.S. clinical trial is designed to assess overall survival and vaccine safety, with vaccine immunogenicity as a secondary endpoint in HLA-A2+ patients with stage IIIb, IV or recurren
'"/>